Loading data for LNAI — first visit, this takes a few seconds.
Lunai Bioworks Inc. (LNAI)
NasdaqCM: LNAI
· Real-Time Price · USD
2.60
+0.21 (8.79%)
At close: Sep 09, 2026, 8:00 PM
The price, the headline numbers and the latest news, in one place.
Lunai Bioworks Inc. (LNAI) Stock Price, Analysis & Data
No data available
| Bid | 2.08 |
| Market Cap | 11.8M |
| Revenue (ttm) | 20.9K |
| Net Income (ttm) | -128M |
| 0.34 | |
| -61.52 | |
| n/a | |
| n/a | |
| P/B (ttm) | -1.22 |
| P/S (ttm) | 565.06 |
| Earnings Date | Sep 28, 2026 |
| Ask | 3.07 |
| Volume | 60,642 |
| Avg. Volume (20D) | 986,022 |
| Open | 2.39 |
| Previous Close | 2.39 |
| Day's Range | 2.39 - 2.93 |
| 52-Week Range | 1.21 - 17.52 |
| Analyst | n/a |
| Price Target | n/a |
| Dividends | n/a |
| Ex-Dividend Date | n/a |
About LNAI
Lunai Bioworks Inc., a pre-clinical stage biotechnology company, provides medicine, diagnostics, and biodefense products the United States and the Netherlands. It operates through three segments, RENB, BioSymetrics, and RENC. The company is developing a genetically modified allogeneic dendritic cell therapeutic vaccines, including RENB-DC11 to treat solid tumors primarily for pancreatic tumors; and RENB-DC20 for the treatment of breast cancer. It...
Industry Biotechnology
Sector Healthcare
IPO Date Feb 7, 2018
Employees 29
Stock Exchange NasdaqCM
Ticker Symbol LNAI
Website https://www.lunaibioworks.com
Financial Performance
In 2025, Lunai Bioworks's revenue was 0, an increase of undefined% compared to the previous year's 0. Earnings were -178.01M, an increase of 101.31%.
Financial StatementsEarnings Surprise
Lunai Bioworks has released their quarterly earnings on Invalid Date:
- Revenue of n/a misses estimates by $0, with NaN% YoY growth.
- EPS of misses estimates by , with NaN% YoY growth.
Lunai Bioworks Inc. is scheduled to release its earnings on Sep 28, 2026, after market closes.
Analysts project revenue of ... Upgrade
Analysts project revenue of ... Upgrade
